Qureight

Company Overview

Qureight is an imaging analytics company based in Cambridge, UK, focused on accelerating clinical trial development for lung and heart diseases through data curation and AI-powered decision making. Founded in 2018, Qureight works with pharmaceutical companies, contract research organizations, and hospitals to curate data and help get the best drugs approved for patients who need them most.

Products Overview

Qureight offers an AI-powered technology stack that enables collaborative analysis of imaging, clinical data and biomarkers. Their platform allows partners to run AI-based data analytics on complex trial data including:

• AI-based image algorithms for CT scans
• AI-assisted workflows
• Central image read cloud-based technology
• Zero-footprint medical imaging viewing with annotation capabilities
• Fast and efficient AI-guided central read image workflows for clinical trials
• Ability to generate synthetic study arms
• AI-powered quantitative imaging analysis of CT scans, including quantification of lung volumes, airways, pulmonary vessels and fibrosis

Founding Team

The company was co-founded by Dr. Muhunthan Thillai, who serves as the CEO. Dr. Thillai has over 20 years of experience in thoracic medicine and is a board-certified Pulmonologist. He qualified as a doctor from Imperial College London and holds a PhD in molecular immunology from the same institution.

Problem and Market Fit

Qureight is addressing the challenges in clinical trial development for lung and heart diseases, particularly in areas like interstitial lung diseases, pulmonary hypertension, and lung cancer. These conditions can be difficult to diagnose, monitor, and develop effective treatments for due to their complexity. Qureight’s AI-powered analytics platform aims to uncover powerful insights from complex trial data, potentially accelerating drug development and improving patient outcomes.

Business Model

Qureight’s business model involves partnering with pharmaceutical companies, contract research organizations, and hospitals to provide data curation and AI-powered analytics services. They likely generate revenue through licensing their platform, providing data analysis services, and potentially through collaborative research projects.

Funding and Runway

While specific funding details are not provided in the given material, it is mentioned that Qureight has received investment from several venture capital firms including Cambridge Angels, Meltwind, CMS Ventures, Playfair Capital, and Ascension Ventures.

Competitive Landscape

The competitive landscape is not explicitly detailed in the provided information. However, given Qureight’s focus on AI-powered analytics for clinical trials in lung and heart diseases, they likely compete with other health tech companies specializing in clinical trial optimization and medical imaging analysis.

Customers

Qureight works with a range of prominent customers across different sectors:

Biopharma companies: - AstraZeneca - Roche - MSD (Merck) - Takeda - Galapagos - Galecto - Vicore Pharma - Istesso

Hospitals: - University Hospitals Birmingham NHS Foundation Trust - Royal Papworth Hospital - Guy’s and St Thomas’ NHS Foundation Trust - Queen Elizabeth Hospital King’s Lynn - University Hospital Southampton

Contract Research Organizations: - PPD - Clario - Criterium - VIDA

Relevant News

1. July 28, 2024: Qureight appointed Dr. Steven Bishop as Chief Data Officer.

2. May 2, 2024: Dr. Simon Walsh was appointed as Chief Scientific Officer.

3. December 12, 2023: Qureight announced a partnership with King Faisal Specialist Hospital and Research Centre for an innovative lung transplant research pilot.

4. November 20, 2023: Javier Alvarez Valle was appointed to Qureight’s Scientific Advisory Board.

5. September 12, 2023: Claus Torp Jensen was appointed as Chairperson of the Qureight Board.

6. September 6, 2023: Qureight and Vicore Pharma released results characterizing lung disease patients who may be more responsive to C21 treatment.

7. July 23, 2023: Qureight entered into a multi-year collaboration with AstraZeneca on lung disease research.

8. September 21, 2022: Dr. Xose Fernandez joined Qureight’s Scientific Advisory Board.

9. September 15, 2022: Qureight gained ISO13485 certification, demonstrating their commitment to maintaining a high-quality management system for the design of medical devices.